One of the potential compounds that regulate ATF4 expression is Exendin-4 (Exenatide), the first glucagon-like peptide 1 receptor agonist used clinically as a therapeutic agent for type 2 diabetes [58]. Here, ATF4 is linked to type 2 diabetes mellitus.